Multiple Thrombotic Events in a 67-Year-Old Man 2 Weeks After Testing Positive for SARS-CoV-2: A Case Report
Authors:
- 22 July 2020
- journal article
- research article
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 21, e925786
Abstract
BACKGROUND:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the viral pathogen responsible for coronavirus disease 2019 (COVID-19), a pandemic respiratory illness. While many patients experience mild to moderate symptoms, severely affected patients often progress to acute respiratory distress syndrome (ARDS). Specific to COVID-19, abnormal coagulability appears to be a principal instigator in the progression of disease severity and mortality. In this report we summarize a case of COVID-19 in which extreme thrombophilia led to patient demise. CASE REPORT:A 67-year-old man in New York presented to the hospital 14 days after testing positive for SARS-CoV-2 at an outpatient site. His initial presenting symptoms included sore throat, headache, fever, and diarrhea. He was brought in by his wife after developing sudden onset confusion and dysarthria. The patient’s clinical picture, which was unstable on presentation, further deteriorated to involve significant desaturations, generalized seizure activity, and cardiac arrest requiring resuscitation. Upon return to spontaneous circulation, the patient required intensive care unit admission, mechanical ventilation, and vasopressor increases. Comprehensive workup uncovered coagulopathy with multiple thrombotic events involving the brain and lungs as well as radiographic evidence of severe lung disease. In the face of an unfavorable clinical picture, the family opted for comfort care measures. CONCLUSIONS:In this case report on a 67-year-old-man with COVID-19, we present an account of extreme hypercoagulability that led to multiple thrombotic events eventually resulting in the man’s demise. Abnormal coagulation 14 days from positive testing raises the question of whether outpatients with COVID-19 should be screened for hypercoagulability and treated with prophylactic anticoagulation/antiplatelet agents.Keywords
This publication has 9 references indexed in Scilit:
- Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forumJournal of Thrombosis and Thrombolysis, 2020
- Covid-19 in Critically Ill Patients in the Seattle Region — Case SeriesNew England Journal of Medicine, 2020
- Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathyJournal of Thrombosis and Haemostasis, 2020
- ISTH interim guidance on recognition and management of coagulopathy in COVID‐19Journal of Thrombosis and Haemostasis, 2020
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected PneumoniaNew England Journal of Medicine, 2020
- Prominent changes in blood coagulation of patients with SARS-CoV-2 infectionClinical Chemistry and Laboratory Medicine (CCLM), 2020
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020
- Viral-associated thrombotic microangiopathiesHematology/Oncology and Stem Cell Therapy, 2011
- A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction ScoreJournal of Thrombosis and Haemostasis, 2010